| 1 | Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database. (Janus SE, Heisler AC, Al Jammal M, Chahine N, Chami T, Hajjari J, Mously H, Badhwar A, Arora S, Al-Juhaishi T, Al-Kindi SG, Hoit BD) Curr Probl Cardiol 2022 Nov;47(11):101345 3 Citations |
| 2 | Retinal cotton wool spot associated with cladribine therapy for multiple sclerosis. (Gummi R, Walsh RD, Ahmad B) Mult Scler Relat Disord 2021 Feb;48:102661 2 Citations |
| 4 | Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia. (Mushtaq MU, Harrington AM, Chaudhary SG, Michaelis LC, Carlson KB, Abedin S, Runass L, Callander NS, Fallon MJ, Juckett M, Hall AC, Hematti P, Mattison RJ, Atallah EL, Guru Murthy GS) Leuk Lymphoma 2021 Jan;62(1):158-166 10 Citations |
| 2 | Langerhans Cell Histiocytosis of the Orbit: Spectrum of Disease and Risk of Central Nervous System Sequelae in Unifocal Cases. (Esmaili N, Harris GJ) Ophthalmic Plast Reconstr Surg 2016;32(1):28-34 19 Citations |
| 1 | I have good news! You have leukemia. (Kurzrock R) Clin Dermatol 2007;25(3):350-2 1 Citation |
| 1 | CASE 1. Langerhans cell histiocytosis of the thyroid. (Braiteh F, Kurzrock R) J Clin Oncol 2006 Jan 20;24(3):522-3 17 Citations |
| 1 | 2-chlorodeoxyadenosine-associated transient acantholytic dermatosis in hairy cell leukemia patients. (Cohen PR, Kurzrock R) Am J Dermatopathol 1999 Feb;21(1):106-8 11 Citations |
| 1 | Transient acantholytic dermatosis after treatment with 2-chlorodeoxyadenosine. (Cohen PR, Kurzrock R) Acta Derm Venereol 1997 Sep;77(5):412-3 8 Citations |
| 1 | Second cancer risk in hairy cell leukemia: analysis of 350 patients. (Kurzrock R, Strom SS, Estey E, O'Brien S, Keating MJ, Jiang H, Adams T, Talpaz M) J Clin Oncol 1997 May;15(5):1803-10 110 Citations |
| 1 | Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA). (Kroft SH, Tallman MS, Shaw JM, Thangavelu M, Peterson LC) Leukemia 1997 Jan;11(1):170 23 Citations |
| 1 | Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. (Seymour JF, Estey EH, Keating MJ, Kurzrock R) Leukemia 1995 May;9(5):929-32 53 Citations |
| 1 | 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. (O'Brien S, Kurzrock R, Duvic M, Kantarjian H, Stass S, Robertson LE, Estey E, Pierce S, Keating MJ) Blood 1994 Aug 01;84(3):733-8 68 Citations |
| 1 | 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. (Seymour JF, Kurzrock R, Freireich EJ, Estey EH) Blood 1994 May 15;83(10):2906-11 205 Citations |
| 1 | Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). (Estey EH, Kurzrock R, Kantarjian HM, O'Brien SM, McCredie KB, Beran M, Koller C, Keating MJ, Hirsch-Ginsberg C, Huh YO) Blood 1992 Feb 15;79(4):882-7 182 Citations |
| 1 | Hairy cell leukaemia: review of treatment. (Kurzrock R, Talpaz M, Gutterman JU) Br J Haematol 1991 Oct;79 Suppl 1:17-20 25 Citations |
© 2024 Clinical & Translational Science Institute